Clinical trial
Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron Plus Ribavirin Given Bi-weekly in Comparison With PEG-Intron Plus Ribavirin Given Weekly
NCT00863239 is registered in ClinicalTrials.gov with Biolex Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron Plus Ribavirin Given Bi-weekly in Comparison With PEG-Intron Plus Ribavirin Given Weekly
- Lead sponsor
- Biolex Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2009
- Completion date
- November 30, 2011
- Enrollment
- 116 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.